thymopoietin-iii and Bronchiectasis

Follow-up of 114 patients with bronchiectasis has demonstrated that immunomodulation agents levamisole and splenin included in combined treatment augment their therapeutic effect and normalize the immune status of patients. This is manifested by normalization of the amount and functional activity to T-lymphocytes, the content of IgG, IgM and IgA and the autoimmune shifts. A favourable effect was encountered significantly more often than that in patient who were treated by the traditional methods without the use of the immunomodulation agents and in those who were given only levamisole and splenin together with anti-bacterial and hygienic therapy.

Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Bacterial Agents; Bronchiectasis; Drug Evaluation; Drug Therapy, Combination; Humans; Levamisole; Middle Aged; Spleen; Sulfanilamides; Thymopoietins; Thymus Hormones

Topics: Adult; Bronchiectasis; Combined Modality Therapy; Humans; Levamisole; Middle Aged; Thymopoietins; Thymus Hormones

Patients with acute lung abscesses and bronchiectatic diseases manifested deep changes in the immune responsiveness, which were largely of compensatory (elevation of IgA content to over 2 mg/ml), immunosuppressive (decrease of lymphocyte blast transformation with PHA down to 52.2 and 48.6%) or autoimmune (increase of spontaneous lymphocyte blast transformation up to 8%) character. In patients with acute lung abscesses, the indicators enumerated tended during treatment toward normalization which was not over in the majority of them by the discharge from hospital. In patients with bronchiectatic disease, that tendency was observable only after additional treatment with immunocorrective drugs (levamisole, splenin).

Topics: Anti-Bacterial Agents; Bronchiectasis; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunotherapy; Levamisole; Lung Abscess; Lymphocyte Activation; Rosette Formation; T-Lymphocytes; Thymopoietins; Time Factors